EUVIMEDPoznaj EUVIMED
Crossref

A Rational Computational Pipeline for the Discovery of a Potent EGF-Mimetic Ligand with In vitro Enhanced Proliferative Activity in Cancer Stem Cells

Ghazaleh Ghavami, Ramin Ebrahimi Kiasari, Mohsen Mesbahi-Nowrouzi, Soroush Sardari

Applied Biochemistry and Biotechnology · 2026-12 · 198 (12) · 10528-10544

DOI: 10.1007/s12010-026-05903-7 ↗

At a glance

Journal article in Applied Biochemistry and Biotechnology, published online on 2026-11-05. Written by Ghazaleh Ghavami and 3 co-authors. Institution: Drug Design and Bioinformatics Unit, Medical Biotechnology Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran. Major MEDLINE topics: Neoplastic Stem Cells, Epidermal Growth Factor, Cell Proliferation, Biomimetic Materials. 31 references. Funded by: National Institute for Medical Research Development.

AbstraktSubjectsDane bibliograficzneCiteRelated studies

Abstract (original language)

This study developed a novel synthetic biomimetic ligand that replicates Epidermal Growth Factor (EGF) using an integrated in silico and in vitro pipeline. A fragment-based design strategy generated a virtual library, which was filtered to identify drug-like compounds with high predicted affinity for the EGFR. The lead compound, DB09210, demonstrated exceptional biomimetic properties. In human fibroblasts, it sustained cell viability comparably to fetal bovine serum. Notably, in 3D cultures of gastric cancer stem cells (GCSCs), DB09210 exhibited potent, time- and dose-dependent activity, surpassing native EGF in promoting proliferation after 7 days. The observed maintenance of CD133 + expression can be interpreted as evidence for preserved stemness, implying the compound may act as a potent functional mimetic mechanism. While its potent enrichment of cancer stem cells requires therapeutic caution, DB09210 is a powerful tool compound. Its ability to reliably expand stem cell populations under defined, serum-free conditions holds significant promise for regenerative medicine, organoid biobanking, and advanced ex vivo drug screening platforms.

Subjects

MeSH terms (MEDLINE)

Neoplastic Stem CellsEpidermal Growth FactorCell ProliferationBiomimetic MaterialsHumansLigandsAnimalsErbB ReceptorsCell Line, Tumor

Author keywords

De Novo Drug DesignBiomimetic LigandsCancer Stem Cells (CSCs)Epidermal Growth Factor (EGF)Regenerative Medicine

Substances

Epidermal Growth FactorLigandsErbB Receptors

Authors and institutions

  • Drug Design and Bioinformatics Unit, Medical Biotechnology Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.
  • Drug Design and Bioinformatics Unit, Medical Biotechnology Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran. sardari@pasteur.ac.ir.

Funding

  • National Institute for Medical Research Development

Cite

APA

Ghavami, G., Kiasari, R. E., Mesbahi-Nowrouzi, M., & Sardari, S. (2026). A Rational Computational Pipeline for the Discovery of a Potent EGF-Mimetic Ligand with In vitro Enhanced Proliferative Activity in Cancer Stem Cells. Applied Biochemistry and Biotechnology, 198(12), 10528-10544. https://doi.org/10.1007/s12010-026-05903-7

Vancouver

Ghavami G, Kiasari RE, Mesbahi-Nowrouzi M, Sardari S. A Rational Computational Pipeline for the Discovery of a Potent EGF-Mimetic Ligand with In vitro Enhanced Proliferative Activity in Cancer Stem Cells. Applied Biochemistry and Biotechnology. 2026;198(12):10528-10544. doi:10.1007/s12010-026-05903-7

BibTeX
@article{Ghavami2026,
  author = {Ghavami, Ghazaleh and Kiasari, Ramin Ebrahimi and Mesbahi-Nowrouzi, Mohsen and Sardari, Soroush},
  title = {A Rational Computational Pipeline for the Discovery of a Potent EGF-Mimetic Ligand with In vitro Enhanced Proliferative Activity in Cancer Stem Cells},
  journal = {Applied Biochemistry and Biotechnology},
  year = {2026},
  volume = {198},
  number = {12},
  pages = {10528--10544},
  doi = {10.1007/s12010-026-05903-7}
}
Start for free →